Endeavor Doses First Patient in Phase 2 Oncology Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib)
Open-Label Trial in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations SAN DIEGO–(BUSINESS WIRE)–Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the first patient has been dosed in an open-label Phase 2 study evaluating ENV-101 (taladegib) in patients with advanced solid … [Read more…]